The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Benign prostatic hyperplasia – what do we know?
Open accessAbstract
Objectives: To present historical and contemporary hypotheses on the pathogenesis of benign prostatic hyperplasia (BPH), and the potential implications for current medical therapies. Methods: The literature on BPH was reviewed. BPH is a prevalent disease with significant health and economic impacts on patients and health organisations across the world, whilst the cause/initiation of the disease process has still not been fully determined. Results: In BPH, pathways involving androgens, oestrogens, insulin, inflammation, proliferative reawakening, stem cells and telomerase have been hypothesised in the pathogenesis of the disease. A number of pathways first described >40 years ago have been first rebuked and then have come back into favour. A system of an inflammatory process within the prostate, which leads to growth factor production, stem cell activation, and cellular proliferation encompassing a number of pathways, is currently in vogue. This review also highlights the physiology of the prostate cell subpopulations and how this may account for the delay/failure in treatment response for certain medical therapies. Conclusion: BPH is an important disease, and as the pathogenesis is not fully understood it impacts the effectiveness of medical therapies. This impacts patients, with further research potentially highlighting novel therapeutic avenues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin inhibits the proliferation of benign prostatic epithelial cells
Wang, Z., Xiao, X., Ge, R., Li, J., Johnson, C. W., Rassoulian, C., & Olumi, A. F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173335 · Cited by 29
RetractedLim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
The Development of Human Benign Prostatic Hyperplasia with Age
Berry, S. J., Coffey, D. S., Walsh, P. C., & Ewing, L. L. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)49698-4 · Cited by 2,488
Aromatase Cytochrome P450, The Enzyme Responsible for Estrogen Biosynthesis*
SIMPSON, E. R., MAHENDROO, M. S., MEANS, G. D., KILGORE, M. W., HINSHELWOOD, M. M., GRAHAM-LORENCE, S., AMARNEH, B., ITO, Y., FISHER, C. R., MICHAEL, M. D., et al. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-342 · Cited by 1,537
CD133, a novel marker for human prostatic epithelial stem cells
Richardson, G. D., Robson, C. N., Lang, S. H., Neal, D. E., Maitland, N. J., & Collins, A. T. (2004) · Journal of Cell Science · doi:10.1242/jcs.01222 · Cited by 770
Self-citationInsulin-like Growth Factor Binding Proteins
Rechler, M. M. (1993) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)60444-6 · Cited by 755
Etiology and disease process of benign prostatic hyperplasia
Isaacs, J. T., & Coffey, D. S. (1989) · The Prostate · doi:10.1002/pros.2990150506 · Cited by 558
Origin and evolution of benign prostatic enlargement.
McNeal, J. E. (1978) · PubMed · Cited by 539
Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?
Kramer, G., Mitteregger, D., & Marberger, M. (2007) · European Urology · doi:10.1016/j.eururo.2006.12.011 · Cited by 464
Morgentaler, A., & Traish, A. M. (2009) · European Urology · doi:10.1016/j.eururo.2008.09.024 · Cited by 462
Metadata
- Authors
- Devlin, C. M., Simms, M. S., & Maitland, N. J.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2020-09-24
- Volume
- 127
- Issue
- 4
- Pages
- 389-399
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W3084261092
- Cited by
- 287
- References
- 60
- FWCI
- 24.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benign prostatic hyperplasia – what do we know? https://app.cochat.ai/papers/10.1111/bju.15229
- The paper
- Devlin, C. M., Simms, M. S., & Maitland, N. J. (2021). Benign prostatic hyperplasia – what do we know? BJU International. https://doi.org/10.1111/bju.15229
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.